Helixmith said it has kicked off the phase 2a global clinical trial of its gene therapy, Engensis, also known as VM202, which treats amyotrophic lateral sclerosis (ALS) patients.The clinical trial team, led by Professor Kim Seung-hyun team at Hanyang University Seoul Hospital, has administered the d
Medytox became the largest shareholder of Evolus, a U.S. pharmaceutical company specializing in botulinum toxin (BTX), raising the possibility of the Korean company marketing its products through the new U.S. partner, a local analyst said Friday.Lee Dong-gun, an analyst at Shinhan Investment Corp.,
Medpacto’s research team has developed a novel way to decrease the size of a drug down to nanoparticles and encapsulate it to penetrate the pancreatic cancer tissue easier.The company’s size-switchable nanosystem is designed to deliver two different drugs sequentially for enhanced chemotherapy in ca
Novartis Korea said Thursday that the Ministry of Food and Drug Safety has approved Luxturna, its inherited retinal dystrophy (IRD) treatment.According to the company, the approval marks the first IRD gene therapy for patients with RPE65 gene mutation and has sufficient retinal cells in Korea. The m
Genuone Sciences plans to export 3 billion won ($2.5 million) worth of Neopol Vaginal Soft Capsule, a treatment of vaginal candidiasis and nonspecific bacterial vaginosis, to Algeria through its local partner, Soprophal, for three years.Under an accord, Genu Pharma, the Korean company's subsidiary,
Huons said it would conduct a test to verify how strong the Russian Sputnik V Covid-19 vaccine can protect people against the Delta variant.The company and Korea University's Biosafety Center plan to confirm the preventive efficacy against the Delta variant with an animal model using a hamster for t
Pfizer’s Vyndamax (tafamidis), a treatment for transthyretin amyloid cardiomyopathy (ATTR-CM), got in the European Society of Cardiology’s (ESC) list of recommended drugs for heart failure.However, observers said it is uncertain whether the treatment would be reimbursable in Korea because of its hig
JW Bioscience’s technology using tryptophanyl tRNA synthetase (WRS) as a biomarker for early diagnosis of sepsis, or blood poisoning, has been registered as a source technology from the European Patent Office.The company has secured an advantageous position in the global in-vitro diagnostic market w
Medytox said Wednesday that AbbVie has returned the rights concerning MT10109L, a botulinum toxin candidate, to the Korean company.Medytox licensed out the candidate to Allergan, which is now part of AbbVie, in 2013 and granted the exclusive right to develop and commercialize MT10109L in countries a
The Ministry of Food and Drug Safety confirmed that the risk of harm to the human body of N-nitroso-varenicline (NNV) among medicines containing varenicline, a smoking cessation treatment aid, was very low.Varenicline is the main ingredient in Pfizer's anti-nicotine therapy Champix. Thirty-four Kore
inno.N said that it would collaborate with Novacell technology to develop a peptide-based autoimmune disease treatment.Under the accord, Novacell will discover candidate substances for anti-inflammatory peptides, and inno.N plans to conduct additional research and clinical trials on the substance wi
Biopharmaceutical companies are the biggest beneficiaries of the Covid-19 outbreak, but financial reports of such companies showed that despite their hefty gains, they offered little in social contributions.Local drugmakers have significantly improved their performance due to the outbreak of Covid-1
The first and only targeted therapy to treat hormone receptor-positive (HR+) and human epidermal growth factor receptor 2 negative (HER2-) metastatic breast cancer with PIK3CA gene mutation arrived in Korea recently.However, it is uncertain whether it can get health insurance benefits.In May, Novart
Hanall Biopharma is one of the most frequently mentioned Korean drugmakers when analysts forecast the arrival of a global blockbuster drug. In developing autoimmune disease treatment candidate HL161(batoclimab), there are many ongoing clinical trials of batoclimab by partners in the U.S. and China t
Sanofi-Aventis Korea has confirmed the safety and efficacy profile of Dupixent (ingredient: dupilumab) in treating children with uncontrolled moderate-to-severe atopic dermatitis in recent studies.The company conducted phase 2/3 LIBERTY AD PRESCHOOL clinical trials with 162 patients aged six months
Locally developed drug pipelines have increased rapidly in the past three years, industry data showed.On Monday, the Korea Pharmaceutical and Bio-Pharma Manufacturers Association (KPBMA) released the case study results of new drug pipelines and license transfer conducted for domestic pharmaceutical
JW Pharmaceutical’s anti-gout drug URC102 received certification from the European Patent Office (EPO) as a source technology.The patent is the company’s method to prepare a compound that works as the main ingredient and intermediate of URC102. URC102, developed as a new oral drug, inhibits uric aci
Novartis Korea has introduced its combination therapy of Piqray (ingredient: alpelisib) and fulvestrant, saying it could prolong the treatment period and overall survival (OS) of breast cancer patients with major genetic mutations.In May, the company’s breast cancer drug received approval from the M
The government decided to give reimbursement for CSL Behring’s hemophilia treatment, Abstilla, from June. SK Chemicals developed the original substance of the drug and transferred the technology to CSL Behring in 2009.The key developers of Abstilla separated from SK Chemicals and established TiumBio
Pharmanovia, a U.K.-based multinational pharmaceutical company, said that it has established a Korean branch and appointed Yim Yoon-ah as its first country manager."Founded in 2013 and headquartered in Basildon, U.K., Pharmanovia operates a portfolio of more than 20 brands with over 250 employees in